União Europeia - português - EMA (European Medicines Agency)

astrazeneca ab - acalabrutinib - leucemia, linfocítica, crônica, células b - antineoplastic agents, protein kinase inhibitors, - calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll). calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) who have received at least one prior therapy.

Brasil - português - ANVISA (Agência Nacional de Vigilância Sanitária)

astrazeneca do brasil ltda - acalabrutinibe - inibidores da proteÍna quinase; agentes antineoplÁsicos

Brasil - português - ANVISA (Agência Nacional de Vigilância Sanitária)

astrazeneca do brasil ltda - maleato de acalabrutinibe monoidratado -

Brasil - português - ANVISA (Agência Nacional de Vigilância Sanitária)

achÉ laboratÓrios farmacÊuticos s.a - omeprazol - antiacidos e antiulcerosos

União Europeia - português - EMA (European Medicines Agency)

beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - agentes antineoplásicos - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).

Brasil - português - ANVISA (Agência Nacional de Vigilância Sanitária)

adium s.a. - zanubrutinibe - antineoplasico